Resumen
Neoadjuvant immunochemotherapy (NICT) has demonstrated impressive short-term efficacy, with over half of patients experiencing significant tumor shrinkage and achieving major pathological responses (MPR). These findings highlight the pressing need for further investigation into strategies for organ preservation and radiotherapy adjustments in patients who achieve MPR. Our objective was to utilize non-invasive and accessible clinical assessments to predict pathological response before surgery. By employing enhanced CT scans, esophagograms, and esophagoscopy before and after neoadjuvant treatment, we collected objective and quantitative parameters that reflected the dynamic shrinkage of tumors. Subsequently, we constructed prediction models for pathological response using multivariate logistic regression based on those dynamic parameters. These models accurately predicted pathologic complete response (pCR) (AUC 0.879) and MPR (AUC 0.912) of the primary tumor after neoadjuvant immunochemotherapy. This advancement may significantly aid informed decision-making in patient management.